Get started
Novartis AGNovartis AGNovartis AG

Novartis AG

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsETFsBonds
Full chart
Full chart

Compare with Novartis AG



Key facts today


Novartis (NOVN): Pluvicto approved for use with AR pathway inhibitor plus androgen-deprivation therapy; trial showed 28–33% reduced risk of progression or death vs standard care. 1
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪293.98 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
23.38
Basic EPS (TTM)
6.54 USD
Net income (FY)
‪14.65 B‬ USD
Revenue (FY)
‪57.13 B‬ USD
Shares float
‪1.61 B‬
Beta (1Y)
−0.09

Latest earnings


Last report date
Jul 21, 2026
Report period
Q2 2026
EPS
2.41 USD
Revenue
‪14.41 B‬ USD
Earnings call summary

Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance in key brands and launches, offsetting generic erosion. Full-year guidance is reaffirmed, with growth drivers showing robust momentum and multiple pivotal pipeline readouts expected in H2.

Employees


Employees (FY)
‪75.27 K‬
Change (1Y)
−616−0.81%
Revenue / Employee (1Y)
‪758.98 K‬ USD
Net income / Employee (1Y)
‪194.63 K‬ USD

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Vasant Narasimhan
Website
novartis.com
Headquarters
Basel
Founded
1996
IPO date
May 7, 2001
ISIN
CH0012005267
FIGI
BBG000KSD796
Identifiers
ISIN CH0012005267
CFI code
ESVTFR
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


5.924% YTM
Maturity dateAug 14, 2050
Coupon2.75% (Fixed)
5.920% YTM
Maturity dateMar 18, 2056
Coupon5.70% (Fixed)
5.905% YTM
Maturity dateSep 18, 2054
Coupon4.70% (Fixed)
5.871% YTM
Maturity dateMar 18, 2046
Coupon5.60% (Fixed)
5.869% YTM
Maturity dateNov 5, 2055
Coupon5.30% (Fixed)
5.836% YTM
Maturity dateNov 20, 2045
Coupon4.00% (Fixed)
5.820% YTM
Maturity dateNov 5, 2045
Coupon5.20% (Fixed)
5.797% YTM
Maturity dateMay 6, 2044
Coupon4.40% (Fixed)
5.615% YTM
Maturity dateSep 21, 2042
Coupon3.70% (Fixed)
5.265% YTM
Maturity dateMar 18, 2036
Coupon4.90% (Fixed)
5.195% YTM
Maturity dateNov 5, 2035
Coupon4.60% (Fixed)

See all NVSEF bonds 

ETFs holding the stock


VXUS
Vanguard Total International Stock ETF
Weight0.64%
Market value‪4.29 B‬
VEA
Vanguard FTSE Developed Markets ETF
Weight0.89%
Market value‪2.85 B‬
IEFA
iShares Core MSCI EAFE ETF
Weight1.12%
Market value‪2.15 B‬
CHDVD
iShares Swiss Dividend ETF (CH)
Weight14.34%
Market value‪1.46 B‬
EFA
iShares MSCI EAFE ETF
Weight1.31%
Market value‪1.02 B‬
CHSPI
iShares Core SPI(R) ETF (CH)
Weight12.60%
Market value‪909.63 M‬
SMICHA
UBS ETF (CH) - SMI ETF -CHF dis-
Weight17.31%
Market value‪818.51 M‬
SMIA
UBS ETF (CH) - SMI ETF Units -CHF acc-
Weight17.31%
Market value‪818.51 M‬
VGK
Vanguard FTSEEuropean ETF
Weight1.83%
Market value‪700.94 M‬
VEU
Vanguard FTSE All World Ex US ETF
Weight0.71%
Market value‪682.45 M‬
SCHF
Schwab International Equity ETF
Weight1.01%
Market value‪664.05 M‬

Explore more ETFs 

Frequently asked questions


The current price of NVSEF is 158.52 USD — it has increased by 5.68% in the past 24 hours. Watch Novartis AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Novartis AG stocks are traded under the ticker NVSEF.
NVSEF stock has risen by 3.60% compared to the previous week, the month change is a 3.35% rise, over the last year Novartis AG has showed a 34.82% increase.
We've gathered analysts' opinions on Novartis AG future price: according to them, NVSEF price has a max estimate of 174.54 USD and a min estimate of 116.90 USD. Watch NVSEF chart and read a more detailed Novartis AG stock forecast: see what analysts think of Novartis AG and suggest that you do with its stocks.
NVSEF reached its all-time high on Feb 26, 2026 with the price of 171.29 USD, and its all-time low was 34.25 USD and was reached on Mar 10, 2009. View more price dynamics on NVSEF chart.
See other stocks reaching their highest and lowest prices.
NVSEF stock is 5.37% volatile and has beta coefficient of −0.09. Track Novartis AG stock price on the chart and check out the list of the most volatile stocks — is Novartis AG there?
Today Novartis AG has the market capitalization of ‪288.05 B‬, it has increased by 1.08% over the last week.
Yes, you can track Novartis AG financials in yearly and quarterly reports right on TradingView.
Novartis AG is going to release the next earnings report on Oct 27, 2026. Keep track of upcoming events with our Earnings Calendar.
NVSEF earnings for the last quarter are 2.41 USD per share, whereas the estimation was 2.17 USD resulting in a 11.17% surprise. The estimated earnings for the next quarter are 2.23 USD per share. See more details about Novartis AG earnings.
Novartis AG revenue for the last quarter amounts to ‪14.41 B‬ USD, despite the estimated figure of ‪14.08 B‬ USD. In the next quarter, revenue is expected to reach ‪14.60 B‬ USD.
NVSEF net income for the last quarter is ‪3.19 B‬ USD, while the quarter before that showed ‪3.09 B‬ USD of net income which accounts for 0.00% change. Track more Novartis AG financial stats to get the full picture.
Yes, NVSEF dividends are paid annually. The last dividend per share was 4.75 USD. As of today, Dividend Yield (TTM)% is 2.92%. Tracking Novartis AG dividends might help you take more informed decisions.
Novartis AG dividend yield was 3.38% in 2025, and payout ratio reached 61.77%. The year before the numbers were 3.95% and 67.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Aug 1, 2026, the company has ‪75.27 K‬ employees. See our rating of the largest employees — is Novartis AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novartis AG EBITDA is ‪21.00 B‬ USD, and current EBITDA margin is 40.92%. See more stats in Novartis AG financial statements.
Like other stocks, NVSEF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novartis AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novartis AG technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novartis AG stock shows the strong buy signal. See more of Novartis AG technicals for a more comprehensive analysis.